Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 52 articles: HTML format

Single Articles

March 2024
1. SCHOONOVER KE, Dienel SJ, Holly Bazmi H, Enwright JF 3rd, et al
   Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia.
   Neuropsychopharmacology. 2024 Mar 28. doi: 10.1038/s41386-024-01854.
   PubMed     Abstract available
   
   
   
2. HUANG AS, Kang K, Vandekar S, Rogers BP, et al
   Lifespan development of thalamic nuclei and characterizing thalamic nuclei abnormalities in schizophrenia using normative modeling.
   Neuropsychopharmacology. 2024 Mar 13. doi: 10.1038/s41386-024-01837.
   PubMed     Abstract available
   
   
   
3. SEITZ-HOLLAND J, Aleman-Gomez Y, Cho KIK, Pasternak O, et al
   Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.
   Neuropsychopharmacology. 2024 Mar 2. doi: 10.1038/s41386-024-01814.
   PubMed     Abstract available
   
   
   February 2024
4. CABRERA-MENDOZA B, Aydin N, Fries GR, Docherty AR, et al
   Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach.
   Neuropsychopharmacology. 2024 Feb 23. doi: 10.1038/s41386-024-01833.
   PubMed     Abstract available
   
   
   
5. TRUONG TTT, Liu ZSJ, Panizzutti B, Kim JH, et al
   Network-based drug repurposing for schizophrenia.
   Neuropsychopharmacology. 2024 Feb 6. doi: 10.1038/s41386-024-01805.
   PubMed     Abstract available
   
   
   January 2024
6. PAUL SM, Potter WZ
   Finding new and better treatments for psychiatric disorders.
   Neuropsychopharmacology. 2024;49:3-9.
   PubMed     Abstract available
   
   
   
7. HANSON JE, Yuan H, Perszyk RE, Banke TG, et al
   Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
   Neuropsychopharmacology. 2024;49:51-66.
   PubMed     Abstract available
   
   
   December 2023
8. ARIME Y, Saitoh Y, Ishikawa M, Kamiyoshihara C, et al
   Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia.
   Neuropsychopharmacology. 2023 Dec 4. doi: 10.1038/s41386-023-01769.
   PubMed     Abstract available
   
   
   October 2023
9. WANG DM, Chen DC, Xiu MH, Wang L, et al
   A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naive first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.
   Neuropsychopharmacology. 2023 Oct 30. doi: 10.1038/s41386-023-01760.
   PubMed     Abstract available
   
   
   
10. ROESKE MJ, McHugo M, Rogers B, Armstrong K, et al
    Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.
    Neuropsychopharmacology. 2023 Oct 13. doi: 10.1038/s41386-023-01730.
    PubMed     Abstract available
    
    
    September 2023
11. FAN L, Liang L, Wang Y, Ma X, et al
    Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
    Neuropsychopharmacology. 2023 Sep 26. doi: 10.1038/s41386-023-01741.
    PubMed     Abstract available
    
    
    
12. ZHOU DY, Su X, Wu Y, Yang Y, et al
    Decreased CNNM2 expression in prefrontal cortex affects sensorimotor gating function, cognition, dendritic spine morphogenesis and risk of schizophrenia.
    Neuropsychopharmacology. 2023 Sep 15. doi: 10.1038/s41386-023-01732.
    PubMed     Abstract available
    
    
    
13. RABIN RA, Palaniyappan L
    Brain health in ethnically minority youth at risk for psychosis.
    Neuropsychopharmacology. 2023 Sep 4. doi: 10.1038/s41386-023-01719.
    PubMed    
    
    
    August 2023
14. WEICKERT TW, Weickert CS
    A path to novel, effective treatments for schizophrenia.
    Neuropsychopharmacology. 2023 Aug 14. doi: 10.1038/s41386-023-01705.
    PubMed    
    
    
    
15. TRANTER MM, Aggarwal S, Young JW, Dillon DG, et al
    Reinforcement learning deficits exhibited by postnatal PCP-treated rats enable deep neural network classification.
    Neuropsychopharmacology. 2023;48:1377-1385.
    PubMed     Abstract available
    
    
    July 2023
16. JIANG H, Chen P, Sun Z, Liang C, et al
    Assisting schizophrenia diagnosis using clinical electroencephalography and interpretable graph neural networks: a real-world and cross-site study.
    Neuropsychopharmacology. 2023 Jul 25. doi: 10.1038/s41386-023-01658.
    PubMed     Abstract available
    
    
    
17. KU BS, Collins M, Anglin DM, Diomino AM, et al
    Associations between childhood ethnoracial minority density, cortical thickness, and social engagement among minority youth at clinical high-risk for psychosis.
    Neuropsychopharmacology. 2023 Jul 12. doi: 10.1038/s41386-023-01649.
    PubMed     Abstract available
    
    
    April 2023
18. HARE SM, Adhikari BM, Mo C, Chen S, et al
    Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow.
    Neuropsychopharmacology. 2023 Apr 28. doi: 10.1038/s41386-023-01587.
    PubMed     Abstract available
    
    
    
19. DUNCAN L, Shen H, Schulmann A, Li T, et al
    Polygenic scores for psychiatric disorders in a diverse postmortem brain tissue cohort.
    Neuropsychopharmacology. 2023;48:764-772.
    PubMed     Abstract available
    
    
    March 2023
20. O'DONNELL P, Dong C, Murthy V, Asgharnejad M, et al
    The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
    Neuropsychopharmacology. 2023 Mar 16. doi: 10.1038/s41386-023-01560.
    PubMed     Abstract available
    
    
    February 2023
21. CHEN X, Song X, Ongur D, Du F, et al
    Association of default-mode network neurotransmitters and inter-network functional connectivity in first episode psychosis.
    Neuropsychopharmacology. 2023 Feb 14. doi: 10.1038/s41386-023-01546.
    PubMed     Abstract available
    
    
    December 2022
22. YANG C, Zhang W, Liu J, Yao L, et al
    Disrupted subcortical functional connectome gradient in drug-naive first-episode schizophrenia and the normalization effects after antipsychotic treatment.
    Neuropsychopharmacology. 2022 Dec 10. doi: 10.1038/s41386-022-01512.
    PubMed     Abstract available
    
    
    
23. EGERTON A, Griffiths K, Casetta C, Deakin B, et al
    Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration.
    Neuropsychopharmacology. 2022 Dec 1. doi: 10.1038/s41386-022-01508.
    PubMed     Abstract available
    
    
    November 2022
24. MOYA NA, Yun S, Fleps SW, Martin MM, et al
    The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
    Neuropsychopharmacology. 2022 Nov 15. pii: 10.1038/s41386-022-01492.
    PubMed     Abstract available
    
    
    
25. FENG N, Palaniyappan L, Robbins TW, Cao L, et al
    Working memory processing deficit associated with a nonlinear response pattern of the anterior cingulate cortex in first-episode and drug-naive schizophrenia.
    Neuropsychopharmacology. 2022 Nov 14. pii: 10.1038/s41386-022-01499.
    PubMed     Abstract available
    
    
    October 2022
26. LENCZ T, Moyett A, Argyelan M, Barber AD, et al
    Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.
    Neuropsychopharmacology. 2022 Oct 5. pii: 10.1038/s41386-022-01470.
    PubMed     Abstract available
    
    
    September 2022
27. VINOGRADOV S, Chafee MV, Lee E, Morishita H, et al
    Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity.
    Neuropsychopharmacology. 2022 Sep 30. pii: 10.1038/s41386-022-01451.
    PubMed     Abstract available
    
    
    
28. HOWES OD, Cummings C, Chapman GE, Shatalina E, et al
    Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes.
    Neuropsychopharmacology. 2022 Sep 2. pii: 10.1038/s41386-022-01426.
    PubMed     Abstract available
    
    
    August 2022
29. SCHWARZER JM, Meyhoefer I, Antonucci LA, Kambeitz-Ilankovic L, et al
    The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis.
    Neuropsychopharmacology. 2022 Aug 18. pii: 10.1038/s41386-022-01385.
    PubMed     Abstract available
    
    
    March 2022
30. ALNAFISAH RS, Reigle J, Eladawi MA, O'Donovan SM, et al
    Assessing the effects of antipsychotic medications on schizophrenia functional analysis: a postmortem proteome study.
    Neuropsychopharmacology. 2022 Mar 30. pii: 10.1038/s41386-022-01310.
    PubMed     Abstract available
    
    
    
31. ZHAO Q, Cao H, Zhang W, Li S, et al
    A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits.
    Neuropsychopharmacology. 2022 Mar 8. pii: 10.1038/s41386-022-01300.
    PubMed     Abstract available
    
    
    
32. TSITSIPA E, Rogers J, Casalotti S, Belessiotis-Richards C, et al
    Selective 5HT3 antagonists and sensory processing: a systematic review.
    Neuropsychopharmacology. 2022;47:880-890.
    PubMed     Abstract available
    
    
    
33. DAO M, Stoveken HM, Cao Y, Martemyanov KA, et al
    The role of orphan receptor GPR139 in neuropsychiatric behavior.
    Neuropsychopharmacology. 2022;47:902-913.
    PubMed     Abstract available
    
    
    February 2022
34. SEHATPOUR P, Javitt DC, De Baun HM, Carlson M, et al
    Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
    Neuropsychopharmacology. 2022;47:711-718.
    PubMed     Abstract available
    
    
    January 2022
35. KIMOTO S, Hashimoto T, Berry KJ, Tsubomoto M, et al
    Expression of actin- and oxidative phosphorylation-related transcripts across the cortical visuospatial working memory network in unaffected comparison and schizophrenia subjects.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01274.
    PubMed     Abstract available
    
    
    
36. CARREIRA FIGUEIREDO I, Borgan F, Pasternak O, Turkheimer FE, et al
    White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01272.
    PubMed     Abstract available
    
    
    November 2021
37. KIEMES A, Gomes FV, Cash D, Uliana DL, et al
    GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia.
    Neuropsychopharmacology. 2021 Nov 6. pii: 10.1038/s41386-021-01213.
    PubMed     Abstract available
    
    
    October 2021
38. KIM M, Lee TH, Park H, Moon SY, et al
    Thalamocortical dysrhythmia in patients with schizophrenia spectrum disorder and individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2021 Oct 4. pii: 10.1038/s41386-021-01180.
    PubMed     Abstract available
    
    
    
39. PELIN H, Ising M, Stein F, Meinert S, et al
    Identification of transdiagnostic psychiatric disorder subtypes using unsupervised learning.
    Neuropsychopharmacology. 2021;46:1895-1905.
    PubMed     Abstract available
    
    
    September 2021
40. TUOMINEN L, Romaniuk L, Milad MR, Goff DC, et al
    Impairment in acquisition of conditioned fear in schizophrenia.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01193.
    PubMed     Abstract available
    
    
    
41. MILLARD SJ, Bearden CE, Karlsgodt KH, Sharpe MJ, et al
    The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01188.
    PubMed     Abstract available
    
    
    
42. EUM S, Hill SK, Alliey-Rodriguez N, Stevenson JM, et al
    Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
    Neuropsychopharmacology. 2021;46:1802-1810.
    PubMed     Abstract available
    
    
    
43. LAM M, Chen CY, Ge T, Xia Y, et al
    Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics.
    Neuropsychopharmacology. 2021;46:1788-1801.
    PubMed     Abstract available
    
    
    August 2021
44. ABDALLAH CG, Mason GF
    Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine.
    Neuropsychopharmacology. 2021 Aug 2. pii: 10.1038/s41386-021-01122.
    PubMed    
    
    
    
45. BRALTEN J, Mota NR, Klemann CJHM, De Witte W, et al
    Genetic underpinnings of sociability in the general population.
    Neuropsychopharmacology. 2021;46:1627-1634.
    PubMed     Abstract available
    
    
    July 2021
46. SMUCNY J, Dienel SJ, Lewis DA, Carter CS, et al
    Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 20. pii: 10.1038/s41386-021-01089.
    PubMed     Abstract available
    
    
    
47. FERRARELLI F, Phillips ML
    PFC neuromodulation with theta burst stimulation to impact behavior and neural network activity in schizophrenia and bipolar disorder.
    Neuropsychopharmacology. 2021 Jul 7. pii: 10.1038/s41386-021-01086.
    PubMed    
    
    
    
48. GOLDWASER EL, Chiappelli J, Kvarta MD, Du X, et al
    White matter in prolonged glucocorticoid response to psychological stress in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 1. pii: 10.1038/s41386-021-01077.
    PubMed     Abstract available
    
    
    June 2021
49. AVRAM M, Grothe MJ, Meinhold L, Leucht C, et al
    Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.
    Neuropsychopharmacology. 2021 Jun 29. pii: 10.1038/s41386-021-01070.
    PubMed     Abstract available
    
    
    
50. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Correction to: Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2021 Jun 24. pii: 10.1038/s41386-021-01062.
    PubMed    
    
    
    May 2021
51. MODINOS G, Richter A, Egerton A, Bonoldi I, et al
    Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
    Neuropsychopharmacology. 2021 May 3. pii: 10.1038/s41386-021-01019.
    PubMed     Abstract available
    
    
    April 2021
52. SEITZ-HOLLAND J, Seethaler M, Makris N, Rushmore J, et al
    The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.
    Neuropsychopharmacology. 2021 Apr 8. pii: 10.1038/s41386-021-00997.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.